Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-06-22
2003-07-15
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S244000
Reexamination Certificate
active
06593351
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to metalloproteinase inhibitors and, more particularly, relates to novel compounds, compositions and methods for prophylaxis and treatment of inflammation, tissue degradation and the like. This invention, in particular, relates to novel carboxylic acid substituted heterocyclic compounds, compositions containing such compounds and methods of use of such compounds. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Metalloproteinase enzymes, such as collagenases, stromelysins and gelatinases, may contribute to the onset or etiology of, or exacerbate disease states which are related to, connective tissue degradation and the like. For example, matrix metalloproteinases, such as collagenases, stromelysins and gelatinases, are thought to be involved in the tissue breakdown observed in rheumatoid arthritis; osteoarthritis; osteopenias (e.g., osteoporosis); periodontitis; gingivitis; corneal, epidermal and gastric ulceration; and tumour metastasis, invasion and growth; in neuroinflammatory disorders, such as myelin degradation (e.g., multiple sclerosis); and in angiogenesis dependent diseases, such as arthritic conditions; cancer; solid tumor growth; psoriasis; proliferative retinopathies; neovascular glaucoma; ocular tumours; angiofibromas; hemangiomas; nephritis; pulmonary inflammation; and restenosis.
WO 96/33172 discloses N-arylsulfonyl and N-heteroarylsulfonyl substituted 6 membered ring heterocycle hydroxamic acid derivatives, such as N-arylsulfonyl- and N-heteroarylsulfonyl-piperidinyl-2-hydroxamic acid compounds, and their preparation and use as inhibitors of matrix metalloproteinases and TNF production.
EP 606046 discloses N-arylsulfonyl and N-heteroarylsulfonyl substituted 5-6 membered ring heterocycle hydroxamic acid derivatives, such as N-arylsulfonyl- and N-heteroarylsulfonyl-piperidinyl-2-hydroxamic acid compounds and N-arylsulfonyl- and N-heteroarylsulfonyl-1,2,3,4-tetrahydroisoquinolinyl-2-hydroxamic acid compounds, preparation and use as inhibitors of matrix metalloproteinases.
WO 97/18194 discloses certain cyclic and heterocyclic N-substituted &agr;-substituted iminohydroxamic and carboxylic acids, and their preparation and use as inhibitors of matrix metalloproteinases.
EP 803505 discloses optionally substituted aryl fused N-heterocycles and their preparation and use as inhibitors of metalloproteinases.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to selected metalloproteinase inhibitory compounds, analogs and pharmaceutically acceptable salts and prodrugs thereof. The subject compounds are characterized as carboxylic acid substituted heterocyclic compounds. The compounds are useful in the prophylaxis and treatment of inflammation, tissue degradation and related diseases. Therefore, this invention also encompasses pharmaceutical compositions and methods for prophylaxis and treatment of inflamation, tissue degradation and related diseases. The subject invention also relates to processes for making such compounds, as well as to intermediates useful in such processes.
REFERENCES:
patent: 039051 (1985-07-01), None
patent: 606046 (1994-07-01), None
patent: 803505 (1997-10-01), None
patent: WO 96/29313 (1996-09-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 97/18194 (1997-05-01), None
Gibson et al., J Org. Chem., 59:3216 (1994), “Selective Removal of an N-Boc Protecting Group in the Presence of tert-Butyl Ester and Other Acid-Sensitive Groups”.
Svensson et al., Drug Metabolism Reviews, 19(2), 165-194 (1988), “The Design and Bioactivation of Presystemically Stable Prodrugs”.
Bundgaard, J. Med. Chem., 32(12), 2503 (1989), “A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group”.
Baldwin et al., Tetrahedron, 45(19), 6309 (1989), “Non-Proteinogenic Amino Acid Synthesis”.
Schuster et al., Angew. Chem. Int. Ed. Engel, 36:2036-2056 (1997), “Olefin Metathesis in Organic Chemistry”.
Ninomiya et al., Tetrahedron, 30:2151 (1974), “Phosphorus in Organic Synthesis-VII1”.
Wadsworth, Organic Reactions, 25:73-253 (1977), Chapter 25, “Organic Reactions”.
Rabjohn, Organic Reactions, 24:261-415 (1976), Chapter 24 “Organic Reactions”.
Nagasawa et al., J. Med. Chem., 14(6), 501-508 (1971), “Medium Ring Homologs of Proline as Potential Amino Acid Antimetabolites”.
Josey John A.
Koch Kevin
Termin Andreas
Amgen Inc.
Kifle Bruck
Person Richard V.
Ungemach Frank S.
LandOfFree
Carboxylic acid substituted heterocycles, derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxylic acid substituted heterocycles, derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxylic acid substituted heterocycles, derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3039127